Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 6;11(10):1469.
doi: 10.3390/biom11101469.

Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature

Konstantin Schlick  1   2 , Dominik Kiem  1   2 , Richard Greil  1   2   3
Affiliations
Review

Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature

Konstantin Schlick et al. Biomolecules. .

Abstract

Pancreatic adenocarcinoma carries a devastating prognosis. For locally advanced and metastatic disease, several chemotherapeutic regimens are currently being used. Over the past years, novel approaches have included targeting EGFR, NTRK, PARP, K-Ras as well as stroma and fibrosis, leading to approval of NTRK and PARP inhibitors. Moreover, immune check point inhibitors and different combinational approaches involving immunotherapeutic agents are being investigated in many clinical trials. MiRNAs represent a novel tool and are thought to greatly improve management by allowing for earlier diagnosis and for more precise guidance of treatment.

Keywords: chemoresistance; immunotherapy; miRNAs; pancreatic cancer; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overview of selected therapeutic targets in locally advanced/metastatic pancreatic carcinoma. Red indicates that therapies have already been approved for this tumor entity.
See this image and copyright information in PMC

References

    1. McGuigan A., Kelly P., Turkington R.C., Jones C., Coleman H.G., McCain R.S. Pancreatic cancer, A review of clinical diagnosis, epidemiology, treatment and outcomes. World J. Gastroenterol. 2018;24:4846–4861. doi: 10.3748/wjg.v24.i43.4846. - DOI - PMC - PubMed
    1. Nevala-Plagemann C., Hidalgo M., Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat. Rev. Clin. Oncol. 2020;17:108–123. doi: 10.1038/s41571-019-0281-6. - DOI - PubMed
    1. Zeng S., Pöttler M., Lan B., Grützmann R., Pilarsky C., Yang H. Chemoresistance in Pancreatic Cancer. Int. J. Mol. Sci. 2019;20:4504. doi: 10.3390/ijms20184504. - DOI - PMC - PubMed
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 2020;70:7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. Vaishampayan U.N. An evaluation of olaparib for the treatment of pancreatic cancer. Expert Opin. Pharmacother. 2021;22:521–526. doi: 10.1080/14656566.2020.1837113. - DOI - PubMed

Substances